Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Francque

Showing results (131-140 of 177) with videos related to

Pageof 18
Sort By:
Plos One|February 29, 2024
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical informationMatthew McTeer, Douglas Applegate, Peter Mesenbrink, et al.
JCI Insight|July 7, 2017
Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontinPhilippe Lefebvre, Fanny Lalloyer, Eric Baugé, et al.
The Lancet. Gastroenterology & Hepatology|August 9, 2020
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation studyStephen A Harrison, Vlad Ratziu, Jérôme Boursier, et al.
Gastroenterology|January 15, 2016
Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With CorticosteroidsChristophe Moreno, Pierre Deltenre, Christelle Senterre, et al.
Nature Communications|July 1, 2014
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver diseaseYang-Lin Liu, Helen L Reeves, Alastair D Burt, et al.
Hepatology (Baltimore, Md.)|August 24, 2017
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosisScott L Friedman, Vlad Ratziu, Stephen A Harrison, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 9, 2023
Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 PatientsClémence M Canivet, Ming-Hua Zheng, Sami Qadri, et al.
Journal of Hepatology|November 17, 2023
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASHMarkus Boesch, Andreas Lindhorst, Rita Feio-Azevedo, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cellsNicolaas Van Renne, Fleur Ballet, Stijn Van Hees, et al.
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Pageof 18

Showing results (131-140 of 177) with videos related to

Sort By:
Pageof 18
Plos One|February 29, 2024
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical informationMatthew McTeer, Douglas Applegate, Peter Mesenbrink, et al.
JCI Insight|July 7, 2017
Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontinPhilippe Lefebvre, Fanny Lalloyer, Eric Baugé, et al.
The Lancet. Gastroenterology & Hepatology|August 9, 2020
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation studyStephen A Harrison, Vlad Ratziu, Jérôme Boursier, et al.
Gastroenterology|January 15, 2016
Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With CorticosteroidsChristophe Moreno, Pierre Deltenre, Christelle Senterre, et al.
Nature Communications|July 1, 2014
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver diseaseYang-Lin Liu, Helen L Reeves, Alastair D Burt, et al.
Hepatology (Baltimore, Md.)|August 24, 2017
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosisScott L Friedman, Vlad Ratziu, Stephen A Harrison, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 9, 2023
Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 PatientsClémence M Canivet, Ming-Hua Zheng, Sami Qadri, et al.
Journal of Hepatology|November 17, 2023
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASHMarkus Boesch, Andreas Lindhorst, Rita Feio-Azevedo, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cellsNicolaas Van Renne, Fleur Ballet, Stijn Van Hees, et al.
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Pageof 18